BUZZ-Shanghai Junshi's HK shares climb on new drug application plan for cancer treatment

Reuters11-25
BUZZ-Shanghai Junshi's HK shares climb on new drug application plan for cancer treatment

** Hong Kong-listed shares of Shanghai Junshi Biosciences 1877.HK rise 5.9% to HK$25.2, their biggest intraday pct gain since October 31

** Stock touches its highest level since November 18, and set for a second session of gains

** Shanghai-listed shares 688180.SS climb 3.5% to 37.52 yuan, their highest point since November 19

** The China-based innovative drug developer plans to submit new drug application of its product toripalimab injection (code: JS001sc) to regulatory authorities in the near future

** JS001sc is a subcutaneous injection for treatment of recurrent or metastatic non-squamous non-small cell lung cancer

** Phase III clinical study of JS001sc for the first-line treatment of non-squamous non-small cell lung cancer has met the primary endpoints, says Shanghai Junshi

** YTD, Hong Kong stock up 114.9%, Shanghai-listed shares up 36.9%, Hang Seng Biotech Index .HSBIO up 81.5%

(Reporting by Donny Kwok)

((donny.kwok@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment